Samalizumab

• Description :

  Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R) . Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research[1].

• Product Name Alternative :

  ALXN 6000

• UNSPSC :

  12352203

• Target :

  Others

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/samalizumab.html

• Purity :

  99.95

• Solubility :

  10 mM in DMSO

• Smiles :

  [Samalizumab]

• Molecular Weight :

  (144.84 kDa)

• References & Citations :

  [1]Daruka Mahadevan, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019 Aug 23;7 (1) :227.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [1073059-33-2]